Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 120,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have turned bullish on GlaxoSmithKline
Many investors see big health-care firms like Pfizer
Glaxo is hoping to emerge stronger from this volatile period as well. In a move to build presence in emerging markets, Glaxo announced it will purchase a unit of Bristol-Myers Squibb
Having Warren Buffett on board as an owner and providing a dividend yield of 5.2% also give many investors confidence in Glaxo's long-term prospects. In CAPS, 94% of the members rating the company expect it to outperform the market.
Fool contributor Dave Mock recently upgraded the cat food to seafood medley, but is holding off on the Fancy Feast. He owns shares of Pfizer and Johnson & Johnson. Pfizer, Johnson & Johnson, and Glaxosmithkline are Income Investor picks. Pfizer is also an Inside Value recommendation. Exelixis is a Rule Breakers selection. The Fool owns shares of Pfizer and Exelixis. The Fool's disclosure policy made it through school pitching quarters.